However, results from the NCT03091491 trial demonstrated that patients with EGFR-mutant NSCLC exhibited limited therapeutic benefit from either nivolumab monotherapy or the combination of nivolumab and ipilimumab following acquired resistance to EGFR-TKI treatment (13). Here, EGFR is linked to non-small cell lung carcinoma.